Efficacy of Tirzepatide Dual GIP / GLP ‐1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real‐World Propensity Score‐Matched Study
Endocrinology, Diabetes & Metabolism · 2025-03 · 8 (2)
DOI: 10.1002/edm2.70019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 13.02.2025. Verfasst von Ahmed Y Azzam und 16 weiteren Autor:innen. Beteiligte Einrichtung: Montefiore-Einstein Cerebrovascular Research Lab, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Pseudotumor Cerebri, Gastric Inhibitory Polypeptide. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, Qatar National Library, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Introduction
Idiopathic intracranial hypertension (IIH) is a neurological disorder characterised by elevated intracranial pressure (ICP), predominantly affecting obese women of reproductive age. While GLP‐1 receptor agonists have shown promise in IIH management, the potential of dual GIP/GLP‐1 receptor activation through tirzepatide remains unexplored. This study aimed to evaluate tirzepatide's efficacy as an adjunctive therapy in IIH management.
Methods
We conducted a retrospective cohort analysis using the TriNetX Global Health Research Network, analysing data through November 2024. Through propensity score matching, we compared 193 tirzepatide‐exposed IIH patients with 193 controls receiving standard care. Primary outcomes included papilledema severity, visual function, headache frequency, and treatment resistance, monitored at multiple follow‐up timepoints.
Results
Our analysis revealed significant improvements across all measured outcomes in the tirzepatide group. At 24 months, we observed a 68% reduction in papilledema risk (RR 0.320, 95% CI 0.189–0.542, p < 0.001), a 73.9% reduction in visual disturbance and blindness risk (RR 0.261, 95% CI 0.143–0.477, p < 0.001), and a 19.7% reduction in headache risk (RR 0.803, 95% CI 0.668–0.966, p = 0.019). The tirzepatide group demonstrated significant body‐mass index reductions, reaching −1.147 kg/m 2 (95% CI [−1.415, −0.879], p < 0.001) at 24 months compared to controls.
Conclusions
Our results demonstrate that tirzepatide, when used as an adjunctive therapy, provides significant therapeutic benefits in IIH management, particularly in improving papilledema and visual outcomes. Our findings suggest that dual GIP/GLP‐1 receptor activation may offer advantages over traditional single‐receptor therapies, potentially through enhanced metabolic regulation and direct effects on ICP dynamics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Montefiore-Einstein Cerebrovascular Research Lab, Albert Einstein College of Medicine, Bronx, New York, USA.
- Department of Neurological Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
- Department of Radiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
- Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
- October 6 University Hospital, October 6 University, Giza, Egypt.
- Department of Neurosurgery, Jordan Hospital, Amman, Jordan.
ORCID-Profile: Ahmed Y Azzam, Hana J Abukhadijah
Förderung
- NCATS NIH HHS
- Qatar National Library
- National Center for Advancing Translational Sciences
Zitieren
APA
Azzam, A. Y., Essibayi, M. A., Farkas, N., Azab, M. A., Morsy, M. M., Elamin, O., Elswedy, A., Al Zomia, A. S., Alotaibi, H. A., Alamoud, A., Atallah, O., Abukhadijah, H. J., Dmytriw, A. A., Baker, A., Khatri, D., Haranhalli, N., & Altschul, D. J. (2025). Efficacy of Tirzepatide Dual GIP / GLP ‐1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real‐World Propensity Score‐Matched Study. Endocrinology, Diabetes & Metabolism, 8(2). https://doi.org/10.1002/edm2.70019
Vancouver
Azzam AY, Essibayi MA, Farkas N, Azab MA, Morsy MM, Elamin O, et al. Efficacy of Tirzepatide Dual GIP / GLP ‐1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real‐World Propensity Score‐Matched Study. Endocrinology, Diabetes & Metabolism. 2025;8(2). doi:10.1002/edm2.70019
BibTeX
@article{Azzam2025,
author = {Azzam, Ahmed Y and Essibayi, Muhammed Amir and Farkas, Nathan and Azab, Mohammed A and Morsy, Mahmoud M and Elamin, Osman and Elswedy, Adam and Al Zomia, Ahmed Saad and Alotaibi, Hammam A and Alamoud, Ahmed and Atallah, Oday and Abukhadijah, Hana J and Dmytriw, Adam A and Baker, Amanda and Khatri, Deepak and Haranhalli, Neil and Altschul, David J},
title = {Efficacy of Tirzepatide Dual GIP / GLP ‐1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real‐World Propensity Score‐Matched Study},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2025},
volume = {8},
number = {2},
doi = {10.1002/edm2.70019}
}
EUVIMED